As­traZeneca dumps off a mid-stage PAD hope­ful, sound­ing re­treat from a packed mar­ket

Car­dio­vas­cu­lar dis­ease is hav­ing some­what of a re­vival in re­cent years, with a spate of next-gen­er­a­tion heart drugs crack­ing open ma­jor in­di­ca­tions. But for at …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER